FT商学院

Gates Foundation makes unusual investment in experimental cancer trial

Smart Immune is developing technology it hopes will help patients rebuild their immune systems
Karine Rossignol, Smart Immune chief executive

The Bill & Melinda Gates Foundation is making an unusual investment in a biotech start-up’s experimental cancer trial, hoping that its novel technology will one day allow HIV patients to rebuild their immune systems.

Smart Immune, a French cell therapy company led by three female co-founders, has developed technology to coax stem cells, which have the ability to develop into many different cell types, into becoming immature “progenitor” T-cells in a lab. These are then injected into the body, where they mature into a crucial part of the immune system and learn to differentiate between normal cells and threats.

您已阅读21%(664字),剩余79%(2478字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×